Research programme: Ii-Key peptide hybrid vaccines - Antigen Express

Drug Profile

Research programme: Ii-Key peptide hybrid vaccines - Antigen Express

Alternative Names: AEH10p; HPV vaccine - Antigen Express; Human papillomavirus vaccine - Antigen Express; Ii-Key/GAD; Ii-Key/HPV16 E7; Ii-Key/insulin; Ii-Key/MHC

Latest Information Update: 08 Feb 2017

Price : $50

At a glance

  • Originator Antigen Express
  • Class Cancer vaccines; Diagnostic agents; Viral vaccines
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical HIV infections; Human papillomavirus infections; Hypersensitivity; Influenza virus infections; Type 1 diabetes mellitus
  • Discontinued Smallpox

Most Recent Events

  • 08 Feb 2017 Human papillomavirus vaccine is still in preclinical development for Human papillomavirus infections in USA (Antigen Express pipeline, February 2017)
  • 07 Feb 2013 Antigen Express is considering partnerships to develop novel Ii-Key peptide hybrid vaccines as of 07 Feb 2013. http://www.antigenexpress.com/
  • 20 Apr 2009 Pharmacodynamics data from a preclinical trial in cancer presented at the 100th Annual Meeting of the American Association for Cancer Research (AACR-2009) ,
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top